SEARCH

SEARCH BY CITATION

References

  • 1
    Craxì A, Pawlotsky JM, Wedemeyer H, Bjoro K, Flisiak R, Forns X, et al. for the European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis c virus infection. J Hepatol 2011; 55: 245-264.
  • 2
    Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli ME. Hepatis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. HEPATOLOGY 2007; 46: 1350-1356.
  • 3
    Weldt B, Heathcote J, Wedemeyer H, Reichen J, Hofmann P, Zeuzem S, et al. Sustained virological response and clinical outcomes in patients with chronic Hepatitis C and advanced fibrosis. Ann Int Med 2007; 147: 677-684.
  • 4
    Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi l, et al. Predicting mortality risk in patients with compensated HCV-induced cirrosi: a long term prospective study. Am J Gastroenterol 2009; 104: 1147-1158.
  • 5
    Cammà C, Di Bona C, Schepis F, Heathcote J, Zeuzem S, Pockros P, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. HEPATOLOGY 2004; 39: 333-342.
  • 6
    Mallet V, Gilghenkrantz H, Serpaggl J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Int Med 2008; 149: 399-403.
  • 7
    Di Bisceglie A, Shiffman ML, Everson G, Lindsay K, Everhart J, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
  • 8
    Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-1628.
  • 9
    Afdhal NH, Levine R, Brown R Jr, Freilich B, O'Brien M, Brass C. Colchicine vs peg-interferon alfa-2b long term therapy. Results of the four year COPILOT trial [Abstract]. J Hepatol 2008; 48( Suppl 2): S4.
  • 10
    Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140: 1990-1999.
  • 11
    Schulz KF, Altman DG, Moher D, for the CONSORT group. CONSORT 2010 statement: updated guidelines for reporting parallel groups randomized trials. Ann Int Med 2010; 152: 1-8.
  • 12
    www.clinicaltrials.gov (NCT00039871; NCT 00048724;NCT 00049842). Accessed August 26, 2011.
  • 13
    Pagliaro L, Spina GP, D'Amico G, Brocchi E, Caletti GC, Cosentino F, et al., for the Italian Liver Cirrhosis Project. Reliability of endoscopy in the assessment of variceal features. J Hepatol 1987; 4: 93-98.
  • 14
    Bendtsen F, Skovgaard LT, Sørensen TIA, Matzen P. Agreement among multiple observers on endoscopic diagnosis of esophageal varices before bleeding. HEPATOLOGY 1990; 11: 341-347.
  • 15
    Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-2261.
  • 16
    Carrion J, Navasa M, Garrcia-Retortillo M, Garcia-Pagan JC, Crespo C, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
  • 17
    Roberts S, Gordon A, Mclean C, Pedersen J, Bowden S, Thomson K, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C related cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 932-937.
  • 18
    Di Bisceglie AM, Stoddard A, Dienstag J, Shiffmann M, Seef LB, Bonkovsky H, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long term peginterferon. HEPATOLOGY 2011; 53: 1100-1108.